Tøndel C, Jenum S, Tonby K, Christensen EE, Cox RJ, Onyango TB, Skeie LG, Robins H, Klinger M, Banbury B, Bello T, Osborne EJ, Jørgensen MJ, Pourpe S, Leikfoss IS, Jürgens T, Wold H, Torhaug S, Makvandi-Nejad S, Edo-Matas D, Schjetne K, Fredriksen AB, Norheim G, Dyrhol-Riise AM (2026)
SARS-CoV-2 T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1/2 open-label clinical trial
Vaccine, 75, 128290 (in press)
DOI 10.1016/j.vaccine.2026.128290, PubMed 41628524

Langåsdalen I, Müller KE, Villumsen S, Lier T, Pettersen FOD (2026)
Multimorbid woman in her sixties with abdominal pain and dark stools
Tidsskr Nor Laegeforen, 146 (1)
DOI 10.4045/tidsskr.25.0318, PubMed 41556671

Massonnaud CR, Peiffer-Smadja N, Poignard P, Jamard S, Goehringer F, Danion F, Reignier J, de Castro N, Garot D, Lapique EL, Lacombe K, Tolsma V, Faure E, Malvy D, Staub T, Courjon J, Cazenave-Roblot F, Dyrhol Riise AM, Leturnier P, Martin-Blondel G, Roger C, Akinosoglou K, Le Moing V, Piroth L, Sellier P et al. (2025)
Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in patients hospitalized with COVID-19: long-term results from the DisCoVeRy trial
Clin Microbiol Infect (in press)
DOI 10.1016/j.cmi.2025.12.014, PubMed 41429349